4Hodsman AB,Hanley DA,Josse R.Do bisphosphonates reduce the risk of osteoporotic fractures?An evaluation of the evidence to date[J].CMAJ,2002;166(11):1426-30.
5Cauley JA,Thompson DE,Ensrud KC,et al.Risk of mortality followingclinical fractures[J].Osteoporosis Int,2000;11(5):556-61.
6Bilezikian JP.Efficacy of bisphosphonates in reducing fracture risk inpostmenopausal osteoporosis[J].Am J Med,2009;122:S14-21.
7Iwamoto J.Effects of SERMs on bone health.Discrimination of SERMsfrom bisphosphonates in the treatment of postmenopausal osteoporosis[J].Clin Calcium,2010;20(3):396-407.
8Bianchi G,Sambrook P.Oral nitrogen-containing bisphosphonates:a sys-tematic review of randomized clinical trials and vertebral fractures[J].Curr Med Res Opin,2008;24(11):2669-77.
9Jansen JP,Bergman GJ,Huels J,et al.Prevention of vertebral fractures inosteoporosis:mixed treatment comparison of bisphosphonate therapies[J].Curr Med Res Opin,2009;25(9):1861-8.
10Boonen S,Klemes AB,Zhou X,et al.Assessment of the relationship be-tween age and the effect of risedronate treatment in women with postmeno-pausal osteoporosis:a pooled analysis of four studies[J].J Am GeriatrSoc,2010;58(5):658-63.
